St Jude Medical’s ICD leads validated by PHRI

St Jude Medical has announced that its optim-insulated implantable cardioverter defibrillator (ICD) leads have received a preliminary validation from the Population Health Research Institute (PHRI).

The academic health science research institute has completed an initial analysis of data received from ongoing prospective registries monitoring the performance of the Durata and Riata ST Optim ICD leads.

By assessing data from the Optimum, Score and SJ4 Post-Approval registries, the PHRI has found that the leads are associated with very low rates of all-cause insulation abrasion and mechanical failure.

According to the manufacturer, this is indicative of the safety and reliability of the ICD leads.

Dr Mark Carlson, chief medical officer and senior vice-president of research and clinical affairs at St Jude Medical's implantable electronic systems division, said: "We will continue to closely monitor the performance of our high-voltage leads in order to support our efforts to provide safe, reliable devices to physicians around the world."

Earlier this month, the firm reported data from a study that demonstrates the safety and efficacy benefits of its EnligHTN renal denervation system.